Chief Scientific Officer Harlan Robins sold 386,240 shares at $22.01 under a prearranged trading plan.
Adaptive Biotechnologies Corporation’s Chief Scientific Officer Harlan S. Robins sold 386,240 shares for $8.5 million on July 2, 2026, at $22.01 per share. The transaction occurred under a Rule 10b5-1 plan established March 13, 2026, allowing pre-scheduled sales to avoid insider trading concerns.
The sale price exceeded the stock’s July 6, 2026, closing price of $21.50. Adaptive Biotechnologies shares had surged 85% over the prior year. Robins retains 1,019,658 shares, valued at $21.61 million post-transaction.
Adaptive Biotechnologies develops immune medicine platforms, generating revenue through licensing and diagnostic services.